EVALUATION OF METABOLIC SYNDROME PREVALANCE IN ADULTS WITH SEVERE MENTAL DISORDER WHO FOLLOWED IN COMMUNITY MENTAL HEALTH CENTER OF A TRAINING AND RESEARCH HOSPITAL

Introduction: In this study, it was aimed to investigate the prevalance of metabolic syndrome (MS) in individuals with severe mental disorders followed in a community-mental health center (C-MHC). Material and Method: Data related to the research of cases admitted to the C-MHC with the diagnosis of schizophrenia, schizoaffective disorder, atypic psychotic disorder and bipolar mood disorder between January 2014 and June 2018 were examined retrospectively by scanning files and evaluated. Results: A total of 217 patients, 89 (41%) female and 128 (59%) male, were included in the study.The mean age of the sample was 44.5 ± 11.9 year, and when the distribution of psychiatric diagnoses were examined; schizophrenia was present in 77 patients (35.5%), atypical psychosis in 66 patients (30.4%), schizoaffective disorder in 15 patients (6.9%) and bipolar disorder in 59 patients (27.2%). The MS frequency of all patients was found as 46.5% (101). Patients diagnosed with MS were older (p = 0.012), and there was no statistical difference in terms of other sociodemographic and clinical data. Conclusion: The establishment of C-MHC in our country has enabled the regular monitoring of individuals with chronic and severe mental disorders. Because individuals are in long-term medication and psychosocial destructive effects of their disorders, health professionals should closely monitor individuals with severe mental illness in terms of MS. Especially with older age, the risk of MS increases. It is suggested that young people should be followed in terms of MS risk, taking necessary precautions to prevent MS development, and providing care service with a multidisciplinary approach.

BİR EĞİTİM VE ARAŞTIRMA HASTANESİNİN TOPLUM RUH SAĞLIĞI MERKEZİNDE AĞIR RUHSAL BOZUKLUK NEDENİYLE İZLENEN ERİŞKİNLERDE METABOLİK SENDROM SIKLIĞININ DEĞERLENDİRİLMESİ

Giriş: Bu araştırmada, bir toplum ruh sağlığı merkezinde (TRSM) takip edilen ağır ruhsal bozuklukları olan bireylerdeki metabolic sendrom (MS) sıklığının araştırılması amaçlanmıştır. Gereç ve Yöntem: Ocak 2014 ve Haziran 2018 arasında TRSM merkezine başvurmuş, şizofreni, şizoaffektif bozukluk, atipik psikotik bozukluk ve bipolar duygudurum bozukluğu tanılı olguların araştırma ile ilgili verileri dosyaları taranarak retrospektif olarak incelenmiş ve değerlendirilmiştir. Bulgular: Toplam 89 (%41) kadın, 128 (%59) erkek olmak üzere, 217 hasta çalışmaya alınmıştır. Örneklemin yaş ortalaması 44,5 ± 11,9 yıl olup, psikiyatrik tanı dağılımları incelendiğinde;77’si (%35,5) şizofreni, 66’sı (%30,4) atipik psikoz, 15’i (%6,9)şizoaffektif bozukluk, 59’u (%27,2) ise bipolar bozukluk tanısına sahipti. Tüm hastaların MS sıklığı %46,5 (101) olarak bulundu. MS tanısı saptanan hastalar daha ileri yaştaydı (p=0,012), diğer sosyodemografik ve klinik veriler açısından istatistiksel olarak fark yoktu. Sonuç: Ülkemizde TRSM’lerin açılması kronik ve ağır ruhsal bozukluğu olan bireylerin düzenli izlenmesine olanak sağlamıştır. Bireylerin uzun dönem ilaç sağaltımında olmaları ve hastalıklarının psikososyal açıdan yıkıcı etkileri nedeniyle sağlık profesyonelleri ağır ruhsal hastalığı olan bireyleri MS açısından yakından izlemelidir. Özellikle ileri yaşla birlikte MS riski artmaktadır. Genç hastaların MS açısından takibinin yapılması, MS gelişmemesi için gerekli önlemlerin alınması, mutidisipliner yaklaşımla bakım hizmetinin verilmesi önerilir.

PDF

___

Gogia A, Agarwal PK. Metabolic syndrome. Indian J Med Sci 2006; 60(2): 72–81.

Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24(2): 13-8.

Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): 1245-50.

Expert Panel on Detection, Evaluation and T of HBC in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.

Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, American Heart Association et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.

Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world‐wide definition. A consensus statement from the international diabetes federation. Diabetic Medicine 2006;23(5):469-80.

Gül EU, Can DÖ, Hande E, Şahin K, Şahin Ş, Şimşek E. Kırıkkale Toplum Ruh Sağlığı Merkezi’nde Takip Edilen Şizofreni Hastalarının Değerlendirilmesi. Kırıkkale Üniversitesi Tıp Fakültesi Derg 2014; 16(2): 15-9.

Aydin E, Tabo A, Karamustafalioglu K, Alatas G, Aydin E, Yigit S, et al. Revolving door phenomenon: the effect of application of community-based mental health services model at acute psychiatric hospitalization. Anatol J Psychiatry 2014; 15(3): 185-191.

Döngel BD, Tamam L, Kır G. Şizofrenide Görülen Tıbbi Durumlar. Psikiyatr Guncel Yaklasimlar 2017; 9(3): 363-78.

De HM, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10(1): 52-77.

Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications. Dialogues Clin Neurosci 2018; 20(1): 63-73.

Lee J, Nurjono M, Wong A, Salim A. Prevalence of metabolic syndrome among patients with schizophrenia in Singapore. Ann Acad Med 2012; 41(10): 457-62.

Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61(4): 548-53.

Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of Metabolic Syndrome among Inpatients with Schizophrenia. Int J Psychiatry Med 2008; 38(1): 103-12.

Cerit C, Oezten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatr Derg 2008; 19(2): 124-32.

Songur E, Karslıoğlu HE, Soygür H, Ulusoy KS, Özalp E, Şahin CE. Şizofreni ve Şizoaffektif Bozuklukta Metabolik Sendrom. Klin Psikiyatr 2012; 15(2): 80-91.

Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013; 39(2): 306-18.

Van winkel R. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 7(2): 342-8.

Silarova B, Giltay EJ, Van Reedt Dortland A, Van Rossum EFC, Hoencamp E, Penninx BWJH et al. Metabolic syndrome in patients with bipolar disorder: Comparison with major depressive disorder and non-psychiatric controls. J Psychosom Res 2015; 78(4): 391-8.

Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170(3): 265- 74.

Chadda R, Ramshankar P, Deb K, Sood M. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother 2013; 4(3): 174-184.

Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008; 101(1–3): 273–86.

Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160(2): 284-9.

Fawzy N, Shabrawy A El, Youssef A. Prevalence and risk factors of metabolic syndrome among drug-naive psychotic patients. Egyptian Journal of Psychiatry 2015; 36(2): 101-5.

Heald A, Pendlebury J, Anderson S, Narayan V, Guy M, Gibson M et al. Lifestyle factors and the metabolic syndrome in Schizophrenia: A cross-sectional study. Ann Gen Psychiatry 2017; 16(1): 6-12.

Kaya MC, Vırıt O, Altındağ A, Selek S, Bülbül F, Bulut M et al. Şizofrenide metabolik sendrom sıklığı, metabolik sendrom özellikleri ve kullanılan antipsikotiklerle ilişkisi. Arch Neuropsychiatry 2009; 4681): 13-8.

Güveli H, İlnem MC, Yener F, Karamustafalıoğlu N, İpekçioğlu D, Abanoz Z. Antipsikotik Kullanan Şizofreni Hastalarında Metabolik Sendrom Sıklığı ve İlişkili Etmenler. New Symp J 2011; 49(2): 67-76.

Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150(6): 1115-21.

Altinbas K, Darcin A, Guloksuz S, Oral T. Seasonal variation of metabolic syndrome prevalence in bipolar disorder. J Mood Disord 2012; 2(2): 51-57.

Sarisoy G, Boke O, Ozturk A, Akkaya D, Pazvantoglu O, Sahin AR. The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients. Düşünen Adam 2013; 26(3): 267- 75.

Yazıcı MK, Anil Yağcioğlu AE, Ertuğrul A, Eni N, Karahan S, Karaağaoğlu E et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 2011; 261(1): 69-78.

Öyekçin DG. Bir grup şizofreni ve şizoaffektif bozukluk hastasında metabolik sendrom sıklığı. Anatol J Psychiatry 2009; 10(1): 26-33.

Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14(3): 339-47.

Enez Darcin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res 2014; 166(1–3): 201-6.